The Journal of Dermatology 04/2012; · 2.35 Impact Factor
Nishi Nihon Hifuka 01/2010; 72(2):163-168.
[Show abstract] [Hide abstract]
ABSTRACT: The involvement of oxidative stress in the pathogenesis of various skin disorders has been suggested for decades. However, few clinical studies have assessed oxidative stress in skin diseases. The easiest and least invasive method to assess oxidative stress in patients may be the measurement of oxidation products in urine.
This study aims to assess oxidative stress in psoriasis and atopic dermatitis patients.
Urine samples were collected from 29 psoriasis patients (25 males and 4 females), 21 atopic dermatitis patients (14 males and 7 females) and 20 healthy controls (16 males and 4 females). The severity and extent of psoriasis and atopic dermatitis was assessed by their area and severity index. We measured nitrate as a metabolite of nitric oxide, malondialdehyde as a major lipid oxidation product, and 8-hydroxydeoxyguanosine (8-OHdG) as a DNA oxidation marker.
Urinary nitrate and 8-OHdG levels, but not malondialdehyde, were significantly higher in psoriasis patients than those in healthy controls. On the contrary, only urinary nitrate level was significantly higher in atopic dermatitis patients than those in healthy controls. The severity and extent of both psoriasis and atopic dermatitis significantly correlated with urinary nitrate level and malondialdehyde level, but it did not correlate with urinary 8-OHdG level.
Measurement of these three urinary oxidative products is non-invasive. Above all, measurement of urinary nitrate may be most useful in the clinical assessment of oxidative stress in both psoriasis and atopic dermatitis patients. There is a possibility that urinary 8-OHdG level may indicate the different pathogenesis between psoriasis and atopic dermatitis.
Journal of the European Academy of Dermatology and Venereology 12/2009; 23(12):1405-8. · 2.69 Impact Factor
European journal of dermatology: EJD 09/2009; 19(6):644-5. · 1.95 Impact Factor
The Journal of Dermatology 07/2009; 36(6):353-4. · 2.35 Impact Factor
European journal of dermatology: EJD 07/2009; 19(5):507-8. · 1.95 Impact Factor
Journal of the European Academy of Dermatology and Venereology 01/2009; 23(7):844-6. · 2.69 Impact Factor